Here we explore a novel strategy for asymmetric hydrogenation of aromatic pyrazol-5-ols via capture of the active tautomers.
Abstract
An efficient palladium-catalyzed asymmetric hydrogenation of fluorinated aromatic pyrazol-5-ols has been developed via capture of the active tautomers. A wide variety of 2,5-disubstituted and 2,4,5-trisubstituted pyrazolidinones have been synthesized with up to 96% and 95% ee, respectively. The hydrogenation pathway includes Brønsted acid promoted tautomerization of pyrazol-5-ols and Pd-catalyzed asymmetric hydrogenation of the active tautomer.
Pyrazolidinones and related 1,2-diaza-3-one heterocycles are highly desirable building blocks owing to the fact that they frequently set up the core framework of numerous pharmaceutically and agrochemically active compounds.1 Particularly, aside from drug development, optically pure pyrazolidinones have also shown great advantages in synthetic methodology.2 For example, the chiral pyrazolidinones could act as efficient catalysts to promote Diels–Alder reactions, and catalyze kinetic resolution of racemic secondary alcohols.3 Over the last decades, the introduction of fluorine into molecules has received increasing attention in the fields of medicinal, agricultural, and material chemistry, primarily because the isosteric replacement of hydrogen by fluorine enhanced the lipophilicity, metabolic stability, and bioavailability of the parent compounds.4 Consequently, reliable methods toward the facile generation of optically active fluorinated pyrazolidinones would be very desirable in organic synthesis and drug research. However, the methods to chiral pyrazolidinones were still limited to transformation from chiral materials,5 classical chemical resolution3a or kinetic resolution involving pyrazolidinone imides,6 and the synthesis of fluorinated pyrazolidinones was rarely explored. Considering the ready availability and easy preparation of fluorinated pyrazol-5-ols, asymmetric hydrogenation of these compounds would provide atom-economical and straightforward access to optically pure pyrazolidinones (Scheme 1).
Scheme 1. Challenges in the asymmetric hydrogenation of fluorinated pyrazol-5-ols.
Despite much progress having been achieved in the asymmetric hydrogenation of heteroaromatics7 including quinolines,8 iso-quinolines,9 quinoxalines,10 pyridines,11 indoles,12 pyrroles,13 (benzo)furans,14 (benzo)thiophenes,15 imidazoles,16 indolizines,17 pyrimidines,18 and naphthyridines,19 a great number of problems still remain unsettled in this field, such as the catalytic asymmetric hydrogenation of aromatic rings containing free hydroxyl, amido or other electron-enriched functional groups and heteroarenes containing two or more adjacent heteroatoms. The intrinsic problems are apparent: (i) the inherent stability resulting from aromaticity; (ii) the strong coordination effects endowed by the heteroatoms; (iii) the difficulty of controlling the stereoselectivity; (iv) the facile cleavage of the bond between the heteroatoms.20 Therefore, the hydrogenation of this kind of electron-enriched aromatic pyrazol-5-ol with a free hydroxyl and two adjacent nitrogen-atoms is a great and significant challenge. Herein, we wish to report our initial findings on the development of a Pd-catalyzed asymmetric hydrogenation of fluorinated pyrazol-5-ols with excellent enantioselectivities, yields, and diastereoselectivities.
At the outset, the readily available 1-phenyl-3-(trifluoromethyl)-1H-pyrazol-5-ol 1a, which can be synthesized from the easily accessible starting materials ethyl 4,4,4-trifluoro-3-oxobutanoate and phenylhydrazine,21 was selected as the model substrate for investigation. To our disappointment, the hydrogenation failed to proceed in the presence of common Rh, Ru, and Ir catalysts (Scheme 2). This may be ascribed to the strong coordination effects and highly electron-enriched nature of fluorinated pyrazol-5-ols that impeded the hydrogenation.
Scheme 2. Asymmetric hydrogenation of fluorinated pyrazol-5-ol 1a.
In principle, these kinds of substrates exist in three tautomeric forms, i.e. the OH– (form A), the NH– (form B) and the CH–isomer (form C) (Scheme 3).1e,22 A literature search23 and experimental data including X-ray crystal structure24 analysis demonstrated that form A is the most stable and dominant form. In view of the fact that the alkylation of pyrazol-5-ols would selectively lead to O-alkyl derivatives or N-alkyl derivatives as the alkylation products under specific requirements, we supposed that appropriate conditions would promote the tautomerization of the highly aromatic tautomer A to the more active tautomer C. Previous results have demonstrated that trifluoroacetic acid (TFA) could promote 1,4-dihydroxynaphthalene to form its stable tautomer tetralin-1,4-dione,25 and accelerate iminium–enamine isomerization to facilitate hydrogenation.26 On the basis of these analyses, we envisioned that the combination of a Pd catalyst which is excellently tolerant to acid27 and a Brønsted acid could be suitable for the asymmetric hydrogenation of fluorinated pyrazol-5-ols.
Scheme 3. The tautomeric forms of pyrazol-5-ols and the hydrogenation strategy.
To our delight, the exposure of 1a to TFA in dichloromethane furnished the desired pyrazolidinone 2a with 91% ee and 54% conversion using Pd(OCOCF3)2/(S)-BINAP as the catalyst (Table 1, entry 1). When the reaction was carried out in 2,2,2-trifluoroethanol (TFE), the reactivity and enantioselectivity dropped slightly (entry 2). Subsequently, the effects of other acids were investigated, and TFA was the most suitable choice in view of the reactivity and enantioselectivity.
Table 1. Optimization of the asymmetric hydrogenation of pyrazol-5-ol 1a a .
| ||||
| Entry | Catalyst | Additive | Yield (%) b | Ee (%) c |
| 1 | Pd(OCOCF3)2 + L1 | TFA | 54 | 91 |
| 2 d | Pd(OCOCF3)2 + L1 | TFA | 52 | 90 |
| 3 | Pd(OCOCF3)2 + L1 | l-CSA | 46 | 90 |
| 4 | Pd(OCOCF3)2 + L1 | d-CSA | 39 | 90 |
| 5 | Pd(OCOCF3)2 + L1 | TsOH·H2O | 32 | 90 |
| 6 | Pd(OCOCF3)2 + L2 | TFA | 81 | 96 |
| 7 | Pd(OCOCF3)2 + L3 | TFA | 46 | 93 |
| 8 | Pd(OCOCF3)2 + L4 | TFA | 29 | 90 |
| 9 | Pd(OCOCF3)2 + L5 | TFA | 20 | 97 |
| 10 e | Pd(OCOCF3)2 + L2 | TFA | 94 | 96 |
| ||||
aReaction conditions: Pd(OCOCF3)2 (2 mol%), ligand (2.1 mol%), 1a (0.3 mmol), additive (0.3 mmol), H2 (1200 psi), DCM (2 mL), 60 °C, 36 h.
bIsolated yields.
cDetermined by HPLC.
dUsing TFE as solvent.
e48 h.
Further examinations were focused on ligand screening. From the evaluation of the various commercially available chiral axial bisphosphine ligands, excellent enantioselectivity was obtained with ligand L2 (entry 6), providing the product in 96% ee and 81% isolated yield. When the reaction time was prolonged to 48 hours, the yield was further improved without loss of enantioselectivity (entry 10). Therefore, the optimal condition was established as: Pd(OCOCF3)2/L2/TFA in dichloromethane.
With the optimal conditions in hand, exploration of the substrate scope was carried out, and the results are summarized in Table 2. Gratifyingly, a variety of 1-aryl substituted substrates were smoothly converted to the corresponding pyrazolidinones with excellent enantioselectivities (82–96% ee). The electronic properties of the substituents on the phenyl ring had little effect on the activity and enantioselectivity (entry 5 vs. entries 6–8). However, the hydrogenation of 2-o-tolyl-substituted pyrazol-5-ol 1b gave a moderate 82% enantioselectivity and 67% yield (entry 2). When TangPhos L5, which was developed by Zhang's group in 2002,28 was employed and the temperature was elevated to 100 °C, the pyrazol-5-ol substrates (1i–1j) bearing a pentafluoroethyl substituent could also be hydrogenated with excellent enantioselectivities and yields (entries 9 and 10).
Table 2. Pd-catalyzed asymmetric hydrogenation of pyrazol-5-ols 1 a .
| ||||
| Entry | R F | Ar | Yield (%) b | Ee (%) c |
| 1 | CF3 | C6H5 | 94 (2a) | 96 (S) |
| 2 d | CF3 | 2-MeC6H4 | 67 (2b) | 82 (+) |
| 3 | CF3 | 3-MeC6H4 | 93 (2c) | 95 (+) |
| 4 | CF3 | 4-MeC6H4 | 93 (2d) | 96 (+) |
| 5 | CF3 | 4-MeOC6H4 | 94 (2e) | 95 (+) |
| 6 | CF3 | 3-ClC6H4 | 89 (2f) | 95 (+) |
| 7 | CF3 | 3,4-Cl2C6H3 | 90 (2g) | 93 (+) |
| 8 | CF3 | 4-FC6H4 | 93 (2h) | 94 (+) |
| 9 e | C2F5 | C6H5 | 95 (2i) | 94 (–) |
| 10 e | C2F5 | 4-MeC6H4 | 92 (2j) | 95 (–) |
aPd(OCOCF3)2 (2 mol%), (S)-MeO-Biphep (2.1 mol%), 1 (0.3 mmol), H2 (1200 psi), TFA (0.3 mmol), DCM (2 mL), 60 °C, 48 h.
bIsolated yields.
cDetermined by HPLC.
dPd(OCOCF3)2 (4 mol%), (S)-MeO-Biphep (4.2 mol%), 1b(0.2 mmol), H2 (1200 psi), TFA (0.2 mmol), DCM (2 mL), 60 °C, 48 h.
ePd(OCOCF3)2 (4 mol%), (S,S′,R,R′)-TangPhos (5.2 mol%), 1 (0.2 mmol), H2 (1200 psi), l-CSA (0.2 mmol), TFE (2 mL), 100 °C, 48 h.
For the sake of further estimating the application possibility, a range of 4-substituted 3-(trifluoromethyl)-1H-pyrazol-5-ols (3a–3g) were also investigated (Table 3). The substrates with an alkyl-substituent at the 4-position could be hydrogenated smoothly, providing the corresponding the 2,4,5-trisubstituted pyrazolidinone derivatives with high enantioselectivity and diastereoselectivity. The high diastereoselectivity probably results from the thermodynamic stability of the trans products under these harsh acidic conditions. Substrates bearing long alkyl or bulky substituents at the C4 position gave slightly higher enantioselectivities (entry 1 vs. entries 3,6,7).
Table 3. Pd-catalyzed asymmetric hydrogenation of pyrazol-5-ols 3 a .
| ||||
| Entry | R | Ar | Yield (%) b | Ee (%) c |
| 1 | Me | C6H5 | 92 (4a) | 89 (–) |
| 2 | Me | 4-MeC6H4 | 97 (4b) | 88 (+) |
| 3 | Et | C6H5 | 93 (4c) | 94 (+) |
| 4 | Et | 4-MeC6H4 | 92 (4d) | 93 (+) |
| 5 | Et | 3-MeC6H4 | 90 (4e) | 92 (+) |
| 6 | nPr | C6H5 | 95 (4f) | 93 (+) |
| 7 | Bn | C6H5 | 94 (4g) | 95 (4S,5R) |
aPd(OCOCF3)2 (4 mol%), (S,S′,R,R′)-TangPhos (5.2 mol%), 3 (0.2 mmol), H2 (1200 psi), l-CSA (0.2 mmol), TFE (2 mL), 100 °C, 48 h. In all cases dr > 20 : 1.
bIsolated yields.
cDetermined by HPLC.
The absolute configurations of the hydrogenation products 2a and 4g were determined by X-ray diffraction analysis by recrystallization from the solvent mixture dichloromethane–n-hexane.29 The configurations of the other chiral products were assigned by analogy.
In order to verify our hypothesis that the hydrogenation was carried out via capture of the active tautomer, we synthesized three compounds (form A type 5, form B type 6 and form C type 8) and subject them to identical hydrogenation reactions (Scheme 4). As expected, no reaction was observed for the substrate 5; for substrate 6, a low 10% ee and 14% yield were obtained; the CH–form substrate 8 gave an excellent 91% ee with 89% yield. Based on the experimental results and stereochemistry of the products, we proposed that the reaction experienced the process of Brønsted acid promoted tautomerization to form CH–form tautomer C, followed by Pd-catalyzed asymmetric hydrogenation of the active tautomer C to give the optically active pyrazolidinones. This preliminary result demonstrated the practicability of our strategy of asymmetric hydrogenation of the inseparable active isomers to realize hydrogenation of the intractable isomerisable substrates.
Scheme 4. Reactions of the mechanistic investigation. All reactions were carried out under the conditions of Pd(OCOCF3)2 (4 mol%), (S)-MeO-Biphep (5.2 mol%), substrate (0.2 mmol), H2 (1200 psi), TFA (0.2 mmol), DCM (2 mL), 60 °C, 48 h.
Conclusions
An efficient palladium-catalyzed asymmetric hydrogenation of fluorinated aromatic pyrazol-5-ols has been developed via capture of the active tautomers. A wide variety of 2,5-disubstituted and 2,4,5-trisubstituted pyrazolidinone derivatives have been synthesized with up to 96% and 95% ee, respectively. The hydrogenation pathway includes Brønsted acid promoted tautomerization of the pyrazol-5-ols and palladium-catalyzed asymmetric hydrogenation of the active tautomer. This study provides some enlightenment of the application of asymmetric hydrogenation and useful information for the design of new reactions. Further study on applying this novel strategy to other aromatic compounds and exploration of the applications of the chiral pyrazolidinones are in progress in our laboratory.
Acknowledgments
Financial support from the National Natural Science Foundation of China (21372220 and 21125208) is acknowledged.
Footnotes
References
- (a) Jungheim L. N., Sigmund S. K. J. Org. Chem. 1987;52:4007. [Google Scholar]; (b) Indelicato J. M., Pasini C. E. J. Med. Chem. 1988;31:1227. doi: 10.1021/jm00401a026. [DOI] [PubMed] [Google Scholar]; (c) Holmes R. E., Neel D. A. Tetrahedron Lett. 1990;31:5567. [Google Scholar]; (d) Claramunt R. M., Elguero J. Org. Prep. Proced. Int. 1991;23:273. [Google Scholar]; (e) Couloigner E., Cartier D., Labia R. Bioorg. Med. Chem. Lett. 1999;9:2205. doi: 10.1016/s0960-894x(99)00352-2. [DOI] [PubMed] [Google Scholar]; (f) Chen W., Yuan X. H., Li R., Du W., Wu Y., Ding L. S., Chen Y. C. Adv. Synth. Catal. 2006;348:1818. [Google Scholar]; (g) Pezdirc L., Groselj U., Meden A., Stanovnik B., Svete J. Tetrahedron Lett. 2007;48:5205. doi: 10.1021/cc070041s. [DOI] [PubMed] [Google Scholar]; (h) Pezdirc L., Stanovnik B., Svete J. Aust. J. Chem. 2009;62:1661. [Google Scholar]
- Low C. M. R., Black J. W., Broughton H. B., Buck I. M., Davies J. M. R., Dunstone D. J., Hull R. A. D., Kalindjian S. B., McDonald I. M., Pether M. J., Shankley N. P., Steel K. I. M. J. Med. Chem. 2000;43:3505. doi: 10.1021/jm000937a. [DOI] [PubMed] [Google Scholar]
- (a) Gould E., Lebl T., Slawin A. M. Z., Reid M., Smith A. D. Tetrahedron. 2010;66:8992. [Google Scholar]; (b) Ma G., Deng J., Sibi M. P. Angew. Chem., Int. Ed. 2014;53:11818. doi: 10.1002/anie.201406684. [DOI] [PubMed] [Google Scholar]
- (a) Ma J.-A., Cahard D. Chem. Rev. 2004;104:6119. doi: 10.1021/cr030143e. [DOI] [PubMed] [Google Scholar]; (b) Müller K., Faeh C., Diederich F. Science. 2007;317:1881. doi: 10.1126/science.1131943. [DOI] [PubMed] [Google Scholar]; (c) Purser S., Moore P. R., Swallow S., Gouverneur V. Chem. Soc. Rev. 2008;37:320. doi: 10.1039/b610213c. [DOI] [PubMed] [Google Scholar]; (d) Ma J.-A., Cahard D. Chem. Rev. 2008;108:PR1. doi: 10.1021/cr800221v. [DOI] [PubMed] [Google Scholar]; (e) Cahard D., Xu X., Couve-Bonnaire S., Pannecoucke X. Chem. Soc. Rev. 2010;39:558. doi: 10.1039/b909566g. [DOI] [PubMed] [Google Scholar]; (f) Zheng Y., Ma J.-A. Adv. Synth. Catal. 2010;352:2745. [Google Scholar]; (g) Furuya T., Kamlet A. S., Ritter T. Nature. 2011;473:470. doi: 10.1038/nature10108. [DOI] [PMC free article] [PubMed] [Google Scholar]; (h) Nie J., Guo H.-C., Cahard D., Ma J.-A. Chem. Rev. 2011;111:455. doi: 10.1021/cr100166a. [DOI] [PubMed] [Google Scholar]; (i) He H.-R., Huang Y.-Y., Verpoort F. Acta Chim. Sin. 2013;71:700. [Google Scholar]
- Seki C., Hirama M., Sato T., Takeda S., Kohari Y., Ishigaki K., Ohuchi M., Yokoi K., Nakano H., Uwai K., Takano N., Umemura K., Matsuyama H. Heterocycles. 2012;85:1045. [Google Scholar]
- Wang M., Huang Z., Xu J., Chi Y.-R. J. Am. Chem. Soc. 2014;136:1214. doi: 10.1021/ja411110f. [DOI] [PubMed] [Google Scholar]
- For recent reviews on asymmetric hydrogenation of heteroaromatic compounds, see: ; (a) Glorius F. Org. Biomol. Chem. 2005;3:4171. doi: 10.1039/b512139f. [DOI] [PubMed] [Google Scholar]; (b) Lu S.-M., Han X.-W., Zhou Y.-G. Chin. J. Org. Chem. 2005;25:634. [Google Scholar]; (c) Zhou Y.-G. Acc. Chem. Res. 2007;40:1357. doi: 10.1021/ar700094b. [DOI] [PubMed] [Google Scholar]; (d) Wang D.-S., Chen Q.-A., Lu S.-M., Zhou Y.-G. Chem. Rev. 2012;112:2557. doi: 10.1021/cr200328h. [DOI] [PubMed] [Google Scholar]; (e) He Y.-M., Song F.-T., Fan Q.-H. Top. Curr. Chem. 2014;343:145. doi: 10.1007/128_2013_480. [DOI] [PubMed] [Google Scholar]; (f) Ye Z.-S., Shi L., Zhou Y.-G. Synlett. 2014;25:928. [Google Scholar]; (g) Xie J., Zhou Q. Acta Chim. Sin. 2012;70:1427. [Google Scholar]
- For representative reports on asymmetric hydrogenation of quinolines, see: ; (a) Wang W.-B., Lu S.-M., Yang P.-Y., Han X.-W., Zhou Y.-G. J. Am. Chem. Soc. 2003;125:10536. doi: 10.1021/ja0353762. [DOI] [PubMed] [Google Scholar]; (b) Rueping M., Antonchick A. P., Theissmann T. Angew. Chem., Int. Ed. 2006;45:3683. doi: 10.1002/anie.200600191. [DOI] [PubMed] [Google Scholar]; (c) Guo Q.-S., Du D.-M., Xu J. Angew. Chem., Int. Ed. 2008;47:759. doi: 10.1002/anie.200703925. [DOI] [PubMed] [Google Scholar]; (d) Zhou H., Li Z., Wang Z., Wang T., Xu L., He Y., Fan Q.-H., Pan J., Gu L., Chan A. S. C. Angew. Chem., Int. Ed. 2008;47:8464. doi: 10.1002/anie.200802237. [DOI] [PubMed] [Google Scholar]; (e) Wang C., Li C., Wu X., Pettman A., Xiao J. Angew. Chem., Int. Ed. 2009;48:6524. doi: 10.1002/anie.200902570. [DOI] [PubMed] [Google Scholar]; (f) Wang T., Zhuo L.-G., Li Z., Chen F., Ding Z., He Y., Fan Q.-H., Xiang J., Yu Z.-X., Chan A. S. C. J. Am. Chem. Soc. 2011;133:9878. doi: 10.1021/ja2023042. [DOI] [PubMed] [Google Scholar]; (g) Chen Q.-A., Gao K., Duan Y., Ye Z.-S., Shi L., Yang Y., Zhou Y.-G. J. Am. Chem. Soc. 2012;134:2442. doi: 10.1021/ja211684v. [DOI] [PubMed] [Google Scholar]; (h) Wang T., Chen F., Qin J., He Y.-M., Fan Q.-H. Angew. Chem., Int. Ed. 2013;52:7172. doi: 10.1002/anie.201301830. [DOI] [PubMed] [Google Scholar]
- For recent works on asymmetric reduction of isoquinolines, see: ; (a) Lu S.-M., Wang Y.-Q., Han X.-W., Zhou Y.-G. Angew. Chem., Int. Ed. 2006;45:2260. doi: 10.1002/anie.200503073. [DOI] [PubMed] [Google Scholar]; (b) Shi L., Ye Z.-S., Cao L.-L., Guo R.-N., Hu Y., Zhou Y.-G. Angew. Chem., Int. Ed. 2012;51:8286. doi: 10.1002/anie.201203647. [DOI] [PubMed] [Google Scholar]; (c) Iimuro A., Yamaji K., Kandula S., Nagano T., Kita Y., Mashima K. Angew. Chem., Int. Ed. 2013;52:2046. doi: 10.1002/anie.201207748. [DOI] [PubMed] [Google Scholar]; (d) Ye Z.-S., Guo R.-N., Cai X.-F., Chen M.-W., Shi L., Zhou Y.-G. Angew. Chem., Int. Ed. 2013;52:3685. doi: 10.1002/anie.201208300. [DOI] [PubMed] [Google Scholar]
- For representative reports on asymmetric hydrogenation of quinoxalines, see: ; (a) Bianchini C., Barbaro P., Scapacci G., Farnetti E., Graziani M. Organometallics. 1998;17:3308. [Google Scholar]; (b) Tang W., Xu L., Fan Q.-H., Wang J., Fan B., Zhou Z., Lam K.-H., Chan A. S. C. Angew. Chem., Int. Ed. 2009;48:9135. doi: 10.1002/anie.200904518. [DOI] [PubMed] [Google Scholar]; (c) Rueping M., Tato F., Schoepke F. R. Chem.–Eur. J. 2010;16:2688. doi: 10.1002/chem.200902907. [DOI] [PubMed] [Google Scholar]; (d) Chen Q.-A., Wang D.-S., Zhou Y.-G., Duan Y., Fan H.-J., Yang Y., Zhang Z. J. Am. Chem. Soc. 2011;133:6126. doi: 10.1021/ja200723n. [DOI] [PubMed] [Google Scholar]; (e) Qin J., Chen F., Ding Z., He Y.-M., Xu L., Fan Q.-H. Org. Lett. 2011;13:6568. doi: 10.1021/ol2029096. [DOI] [PubMed] [Google Scholar]; (f) Zhang Z., Du H. Angew. Chem., Int. Ed. 2015;54:623. doi: 10.1002/anie.201409471. [DOI] [PubMed] [Google Scholar]
- For representative reports on asymmetric hydrogenation of pyridines, see: ; (a) Studer M., Wedemeyer-Exl C., Spindler F., Blaser H.-U. Monatsh. Chem. 2000;131:1335. [Google Scholar]; (b) Glorius F., Spielkamp N., Holle S., Goddard R., Lehmann C. W. Angew. Chem., Int. Ed. 2004;43:2850. doi: 10.1002/anie.200453942. [DOI] [PubMed] [Google Scholar]; (c) Legault C. Y., Charette A. B. J. Am. Chem. Soc. 2005;127:8966. doi: 10.1021/ja0525298. [DOI] [PubMed] [Google Scholar]; (d) Rueping M., Antonchick A. P. Angew. Chem., Int. Ed. 2007;46:4562. doi: 10.1002/anie.200701158. [DOI] [PubMed] [Google Scholar]; (e) Wang X.-B., Zeng W., Zhou Y.-G. Tetrahedron Lett. 2008;49:4922. [Google Scholar]; (f) Tang W.-J., Tan J., Xu L.-J., Lam K.-H., Fan Q.-H., Chan A. S. C. Adv. Synth. Catal. 2010;352:1055. [Google Scholar]; (g) Ye Z.-S., Chen M.-W., Chen Q.-A., Shi L., Duan Y., Zhou Y.-G. Angew. Chem., Int. Ed. 2012;51:10181. doi: 10.1002/anie.201205187. [DOI] [PubMed] [Google Scholar]; (h) Liu Y., Du H. J. Am. Chem. Soc. 2013;135:12968. doi: 10.1021/ja406761j. [DOI] [PubMed] [Google Scholar]; (i) Chang M., Huang Y., Liu S., Chen Y., Krska S. W., Davies I. W., Zhang X. Angew. Chem., Int. Ed. 2014;53:12761. doi: 10.1002/anie.201406762. [DOI] [PubMed] [Google Scholar]; (j) Kita Y., Iimuro A., Hida S., Mashima K. Chem. Lett. 2014;43:284. [Google Scholar]
- For representative reports on asymmetric hydrogenation of indoles, see: ; (a) Kuwano R., Sato K., Kurokawa T., Karube D., Ito Y. J. Am. Chem. Soc. 2000;122:7614. [Google Scholar]; (b) Baeza A., Pfaltz A. Chen.–Eur. J. 2010;16:2036. doi: 10.1002/chem.200903105. [DOI] [PubMed] [Google Scholar]; (c) Wang D.-S., Chen Q.-A., Li W., Yu C.-B., Zhou Y.-G., Zhang X. J. Am. Chem. Soc. 2010;132:8909. doi: 10.1021/ja103668q. [DOI] [PubMed] [Google Scholar]; (d) Xiao Y.-C., Wang C., Yao Y., Sun J., Chen Y.-C. Angew. Chem., Int. Ed. 2011;50:10661. doi: 10.1002/anie.201105341. [DOI] [PubMed] [Google Scholar]; (e) Duan Y., Li L., Chen M.-W., Yu C.-B., Fan H.-J., Zhou Y.-G. J. Am. Chem. Soc. 2014;136:7688. doi: 10.1021/ja502020b. [DOI] [PubMed] [Google Scholar]
- For reports on asymmetric hydrogenation of pyrroles, see: ; (a) Kuwano R., Kashiwabara M., Ohsumi M., Kusano H. J. Am. Chem. Soc. 2008;130:808. doi: 10.1021/ja7102422. [DOI] [PubMed] [Google Scholar]; (b) Wang D.-S., Ye Z.-S., Chen Q.-A., Zhou Y.-G., Yu C.-B., Fan H.-J., Duan Y. J. Am. Chem. Soc. 2011;133:8866. doi: 10.1021/ja203190t. [DOI] [PubMed] [Google Scholar]
- For reports on asymmetric hydrogenation of (benzo)furans, see: ; (a) Kaiser S., Smidt S. P., Pfaltz A. Angew. Chem., Int. Ed. 2006;45:5194. doi: 10.1002/anie.200601529. [DOI] [PubMed] [Google Scholar]; (b) Ortega N., Urban S., Beiring B., Glorius F. Angew. Chem., Int. Ed. 2012;51:1710. doi: 10.1002/anie.201107811. [DOI] [PubMed] [Google Scholar]; (c) Wysocki J., Ortega N., Glorius F. Angew. Chem., Int. Ed. 2014;53:8751. doi: 10.1002/anie.201310985. [DOI] [PubMed] [Google Scholar]
- For a report on asymmetric hydrogenation of (benzo)thiophenes, see: Urban S., Beiring B., Ortega N., Paul D., Glorius F., J. Am. Chem. Soc., 2012, 134 , 15241 . [DOI] [PubMed] [Google Scholar]
- For a report on asymmetric hydrogenation of imidazoles and oxazoles, see: Kuwano R., Kameyama N., Ikeda R., J. Am. Chem. Soc., 2011, 133 , 7312 . [DOI] [PubMed] [Google Scholar]
- Ortega N., Tang D. D., Urban S., Zhao D., Glorius F. Angew. Chem., Int. Ed. 2013;52:9500. doi: 10.1002/anie.201302218. [DOI] [PubMed] [Google Scholar]
- Kuwano R., Hashiguchi Y., Ikeda R., Ishizuka K. Angew. Chem., Int. Ed. 2015;54:2393. doi: 10.1002/anie.201410607. [DOI] [PubMed] [Google Scholar]
- Zhang J., Chen F., He Y.-M., Fan Q.-H. Angew. Chem., Int. Ed. 2015;54:4622. doi: 10.1002/anie.201411105. [DOI] [PubMed] [Google Scholar]
- For a report on asymmetric hydrogenation of benzisoxazoles with the cleavage of the bond between the heteroatoms, see: Ikeda R., Kuwano R., Molecules, 2012, 17 , 6901 . [DOI] [PMC free article] [PubMed] [Google Scholar]
- Zhang J., Yang S., Zhang K., Chen J., Deng H., Shao M., Zhang H., Cao W. Tetrahedron. 2012;9:2121. [Google Scholar]
- Holzer W., Plagens B., Lorenz K. Heterocycles. 1997;45:309. [Google Scholar]
- Bieringer S., Holzer W. Heterocycles. 2006;68:1825. [Google Scholar]
- ESI.
- (a) Laatsch H. Liebigs Ann. Chem. 1980:140. [Google Scholar]; (b) Kündig E. P., Enriquez-Garcia A., Lomberget T., Bernardinelli G. Angew. Chem., Int. Ed. 2006;45:98. doi: 10.1002/anie.200502588. [DOI] [PubMed] [Google Scholar]; (c) Kündig E. P., Enriquez-Garcia A. Beilstein J. Org. Chem. 2008;4:37. doi: 10.3762/bjoc.4.37. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (a) Zhou X.-Y., Bao M., Zhou Y.-G. Adv. Synth. Catal. 2011;353:84. [Google Scholar]; (b) Wang D.-S., Tang J., Zhou Y.-G., Chen M.-W., Yu C.-B., Duan Y., Jiang G.-F. Chem. Sci. 2011;2:803. [Google Scholar]; (c) Zhou X.-Y., Wang D.-S., Bao M., Zhou Y.-G. Tetrahedron Lett. 2011;52:2826. [Google Scholar]; (d) Yu C.-B., Gao K., Chen Q.-A., Chen M. W., Zhou Y.-G. Tetrahedron Lett. 2012;53:2560. [Google Scholar]; (e) Duan Y., Chen M.-W., Chen Q.-A., Yu C.-B., Zhou Y.-G. Org. Biomol. Chem. 2012;10:1235. doi: 10.1039/c1ob06777j. [DOI] [PubMed] [Google Scholar]
- Duan Y., Li L., Chen M.-W., Yu C.-B., Fan H.-J., Zhou Y.-G. J. Am. Chem. Soc. 2014;136:7688. doi: 10.1021/ja502020b. [DOI] [PubMed] [Google Scholar]
- Tang W., Zhang X. Angew. Chem., Int. Ed. 2002;41:1612. doi: 10.1002/1521-3773(20020503)41:9<1612::aid-anie1612>3.0.co;2-h. [DOI] [PubMed] [Google Scholar]
- ESI.
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.




